What is InMed Pharmaceuticals Inc Annual Revenue?

InMed Pharmaceuticals Inc Annual Revenue rose 11.18%, in the last year to $4.6 M. Its sector's average revenue growth for the last fiscal year was 7.49%.

What is InMed Pharmaceuticals Inc Annual Net Profit?

InMed Pharmaceuticals Inc Annual Net Profit rose 3.42% in the last year to $7.68 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

What is InMed Pharmaceuticals Inc Price to Earning Ratio?

InMed Pharmaceuticals Inc Price to Earning Ratio is -0.45, which is negative.

What is InMed Pharmaceuticals Inc Stock Price?

InMed Pharmaceuticals Inc Stock Price fell 49.48% and underperformed its sector by 58.63% in the past year.

What is InMed Pharmaceuticals Inc Quarterly Revenue?

InMed Pharmaceuticals Inc Quarterly Revenue fell 10.36% YoY to $1.11 M. Its sector's average revenue growth YoY for the quarter was 5.79%.

What is InMed Pharmaceuticals Inc Quarterly Net profit?

InMed Pharmaceuticals Inc Quarterly Net profit fell 74.2% YoY to $2.58 M. Its sector's average net profit growth YoY for the quarter was -41.97%.

What is InMed Pharmaceuticals Inc Debt to Equity Ratio?

InMed Pharmaceuticals Inc Debt to Equity Ratio of 0.1 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is InMed Pharmaceuticals Inc Return on Equity(ROE)?

InMed Pharmaceuticals Inc Return on Equity(ROE) for the last financial year was -72.08%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is InMed Pharmaceuticals Inc Institutional Holding?

InMed Pharmaceuticals Inc Institutional Holding remained the same in the last quarter at 4.73%.

How is the InMed Pharmaceuticals Inc today?

The InMed Pharmaceuticals Inc today is trading in the down by -1.01% at 2.93.

How has InMed Pharmaceuticals Inc performed historically?

The InMed Pharmaceuticals Inc is currently trading down -1.01% on an intraday basis in the past week the index rose 10.98%. The index has been down -41.98% in the past quarter and fell -49.48% in the past year. You can view this in the overview section.

InMed Pharmaceuticals Inc XNAS: INM

InMed Pharmaceuticals Inc Live Share Price Today, Share Analysis and Chart

Name: InMed Pharmaceuticals Inc: Is Infosys Ltd. worth buying?
Item: InMed Pharmaceuticals Inc
Rating: 1.71358325
Author: Trendlyne DVM scores

Download real time

2.93 -0.03 (-1.01%)

81.34% Fall from 52W High

38,142 XNAS Volume

XNAS 22 Apr, 2025 5:30 PM (EDT)

InMed Pharmaceuticals Inc Key Metrics

My Metrics

Select

Market Capitalization Low in industry Unavailable in chosen country	3.5
PE TTM Negative PE TTM Unavailable in chosen country	-0.4
Price to Book Below industry Median Unavailable in chosen country	0.6
Institutional holding current Qtr % Low in industry Unavailable in chosen country	4.7
Revenue Growth Qtr YoY % Negative Revenue Growth Qtr YoY % Unavailable in chosen country	-10.4
Operating Revenue growth TTM % Negative Operating Revenue growth TTM % Unavailable in chosen country	-11.9
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-74.2
Net Profit TTM Growth % Negative Net Profit TTM Growth % Unavailable in chosen country	-24.6
Operating Profit Margin Qtr % Negative Operating Profit Margin Qtr % Unavailable in chosen country	-198.5
Operating Profit Margin TTM % Negative Operating Profit Margin TTM % Unavailable in chosen country	-160.7
Piotroski Score Below industry Median Unavailable in chosen country	2
Rel Perf vs Sector quarter% Unavailable in chosen country	-41.4
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-72.1
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-59.2

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

27.3 / 100

Technically Neutral

41.2 / 100

No estimates available

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

InMed Pharmaceuticals Inc Stock Price Analysis

Day Price Range -1.0% 1 Day return Unavailable in chosen country	2.9 (LTP) 2.83 LowHigh
Week Price Range 11.0% 1 Week return Unavailable in chosen country	2.9 (LTP) 2.53.2 LowHigh
Month Price Range 5.4% 1 Month return Unavailable in chosen country	2.9 (LTP) 1.73.2 LowHigh
52 Week Price Range -49.5% 1 Year return Unavailable in chosen country	2.9 (LTP) 1.715.7 LowHigh

View full Share Price History

InMed Pharmaceuticals Inc Live Price Chart

Switch to TradingView

Fetching data ...

InMed Pharmaceuticals Inc Stock Analysis

InMed Pharmaceuticals Inc stock analysis with key metrics, changes, and trends.

InMed Pharmaceuticals Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$4.6 M	11.18%	positive	Annual Revenue rose 11.18%, in the last year to $4.6 M. Its sector's average revenue growth for the last fiscal year was 7.49%.
Annual Net Profit	$7.68 M	3.42%	positive	Annual Net Profit rose 3.42% in the last year to $7.68 M. Its sector's average net profit growth for the last fiscal year was -32.44%.
Price to Earning Ratio	-0.45	-	negative	Price to Earning Ratio is -0.45, which is negative.
Stock Price	$2.93	-49.48%	negative	Stock Price fell 49.48% and underperformed its sector by 58.63% in the past year.
Quarterly Revenue	$1.11 M	10.36%	negative	Quarterly Revenue fell 10.36% YoY to $1.11 M. Its sector's average revenue growth YoY for the quarter was 5.79%.
Quarterly Net profit	$2.58 M	74.2%	negative	Quarterly Net profit fell 74.2% YoY to $2.58 M. Its sector's average net profit growth YoY for the quarter was -41.97%.
Debt to Equity Ratio	0.1	-	positive	Debt to Equity Ratio of 0.1 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-72.08 %	-72.08%	negative	Return on Equity(ROE) for the last financial year was -72.08%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Institutional Holding	4.73 %	0%	neutral	Institutional Holding remained the same in the last quarter at 4.73%.

VIEW LESS

Loading data..

InMed Pharmaceuticals Inc - Company Profile

What does InMed Pharmaceuticals Inc do?

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.

InMed Pharmaceuticals Inc Management structure

All Gross Remunerations are in USD

Mr. Jonathan Tegge

Interim Chief Financial Officer and Principal Accounting Officer

2024

Gross Remuneration

Year

Ms. N. Netta Jagpal

Chief Financial Officer, Corporate Secretary and Principal Accounting Officer

2024

Gross Remuneration

Year

InMed Pharmaceuticals Inc Board of directors

All Gross Remunerations are in USD

Ms. Janet Grove

Independent Director

2025

Gross Remuneration

Year

InMed Pharmaceuticals Inc Live Share Price Today, Share Analysis and Chart

81.34% Fall from 52W High

InMed Pharmaceuticals Inc Key Metrics

Market Capitalization

PE TTM

Price to Book

ROE Annual %

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

RoA Annual %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

Market Capitalization

PE TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

InMed Pharmaceuticals Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

InMed Pharmaceuticals Inc Live Price Chart

InMed Pharmaceuticals Inc Stock Analysis

InMed Pharmaceuticals Inc stock analysis with key metrics, changes, and trends.

Annual Revenue rose 11.18%, in the last year to $4.6 M. Its sector's average revenue growth for the last fiscal year was 7.49%.

Annual Net Profit rose 3.42% in the last year to $7.68 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

Price to Earning Ratio is -0.45, which is negative.

Stock Price fell 49.48% and underperformed its sector by 58.63% in the past year.

Quarterly Revenue fell 10.36% YoY to $1.11 M. Its sector's average revenue growth YoY for the quarter was 5.79%.

Quarterly Net profit fell 74.2% YoY to $2.58 M. Its sector's average net profit growth YoY for the quarter was -41.97%.

Debt to Equity Ratio of 0.1 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -72.08%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Institutional Holding remained the same in the last quarter at 4.73%.

InMed Pharmaceuticals Inc - Company Profile

What does InMed Pharmaceuticals Inc do?

InMed Pharmaceuticals Inc Management structure

Mr. Jonathan Tegge

Interim Chief Financial Officer and Principal Accounting Officer

Ms. N. Netta Jagpal

Chief Financial Officer, Corporate Secretary and Principal Accounting Officer

InMed Pharmaceuticals Inc Board of directors

Ms. Janet Grove

Independent Director

InMed Pharmaceuticals Inc FAQ

How is InMed Pharmaceuticals Inc today?

InMed Pharmaceuticals Inc today is trading in the red, and is down by -1.01% at 2.93.

How has InMed Pharmaceuticals Inc performed historically?

InMed Pharmaceuticals Inc is currently trading down -1.01% on an intraday basis. In the past week the stock rose 10.98%. stock has been down -41.98% in the past quarter and fell -49.48% in the past year. You can view this in the overview section.